- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To assess the effect of treatment with MK-0822 5 mg once daily on bone metastasis-free survival (defined as time to first bone metastasis or death from any cause) compared to placebo. • To assess the effect of treatment with MK-0822 5 mg once daily in a subset of 300 patients on lumbar spine, total hip, femoral neck, trochanter and total body bone mineral density (BMD) compared to placebo. • To assess the tolerability of treatment with MK-0822 5 mg once daily compared to placebo.
Critère d'inclusion
- Prevention of bone metastases in men with prostate cancer